{"id":"NCT05279131","sponsor":"Almirall, S.A.","briefTitle":"A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis","officialTitle":"A Phase 3, Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% Applied to a Field of Approximately 100 cm2 on the Face or Balding Scalp in Adult Patients With Actinic Keratosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-06-28","primaryCompletion":"2022-12-28","completion":"2022-12-28","firstPosted":"2022-03-15","resultsPosted":"2024-01-23","lastUpdate":"2024-01-23"},"enrollment":105,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Keratosis, Actinic"],"interventions":[{"type":"DRUG","name":"Tirbanibulin ointment 1%","otherNames":[]}],"arms":[{"label":"Tirbanibulin (Klisyri®)","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm\\^2 on the face or balding scalp.","primaryOutcome":{"measure":"Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 5","timeFrame":"Baseline, Day 5","effectByArm":[{"arm":"Tirbanibulin (Klisyri®)","deltaMin":81,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":7,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":105},"commonTop":["Application site pruritus","Application site pain","Dizziness","Paraesthesia","Atrial fibrillation"]}}